Ophthalmic, oral, and intravenous fluoroquinolone anti-infective Used for acute exacerbation of chronic bronchitis, acute sinusitis, bacterial conjunctivitis, community-acquired pneumonia, intra-abdominal infections, skin and skin structure infections, and plague Associated with disabling and potentially irreversible adverse events, including tendonitis, tendon rupture, and peripheral neuropathy.

Composition

Each film coated tablet contains: Moxifloxacin (as hydrocloride) 400mg. (As per Innovator’s Specs).

Indication

MOXIZON is used; For the treatment of acute bacterial exacerbation of chronic bronchitis. For the treatment of acute bacterial sinusitis. For the treatment of mild to moderate community-acquired pneumonia (CAP). For the treatment of skin and skin structure infections. For the treatment of complicated intraabdominal infections including polymicrobial infections such as abscesses. For the treatment of plague, including pneumonic and septicemic plague, and plague prophylaxis due to susceptible isolates. For the treatment of tuberculosis infection† caused by Mycobacterium tuberculosis in combination with other antituberculosis agents as a second line agent. For the treatment of Mycobacterium avium complex infection (MAC) in HIV-infected patients. For the treatment of anthrax. For the treatment of bacterial gastroenteritis and infectious diarrhea. For the treatment of recurrent or persistent non-gonococcal urethritis (NGU). For the treatment of pelvic inflammatory disease (PID). For anthrax prophylaxis after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).